A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients

Inclusion Criteria: * Critically ill patients infected with COVID-19 (clinical/confirmed) * Patient aged 18 years or more of either gender * Illness of any duration with respiratory rate ≥25 breaths/minute, and at least one of the following: * Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or or * SpO2 ≤94% on room air, or * Requiring mechanical ventilation and/or supplemental oxygen * Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. * Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure. Exclusion Criteria: * Pregnant or nursing female. * Patients with history of allergy, hypersensitivity, or any serious reaction to study medication * Patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. * Patient previously enrolled into this study. * Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or HIV. * Patients with a life expectancy judged to be less than five days * ALT/AST \> 5 times the upper limit of normal * Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR \< 30) * Patients not likely to complete the trial as per judgment of the investigator.